0000905718-19-000065.txt : 20190118
0000905718-19-000065.hdr.sgml : 20190118
20190118163223
ACCESSION NUMBER: 0000905718-19-000065
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181218
FILED AS OF DATE: 20190118
DATE AS OF CHANGE: 20190118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EMSTER KURT VON
CENTRAL INDEX KEY: 0001252524
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 19533516
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD
STREET 2: SUITE 350
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4/A
1
crisprfm4a_dec192018.xml
X0306
4/A
2018-12-18
2018-12-19
0
0001674416
CRISPR Therapeutics AG
CRSP
0001252524
EMSTER KURT VON
C/O CRISPR THERAPEUTICS, INC.,
610 MAIN STREET
CAMBRIDGE
MA
02139
1
0
0
0
Common Shares
2018-12-18
4
S
0
62925
29.7047
D
1171268
I
See Footnote
This amended Form 4 is being filed to correct the number of shares sold on December 18, 2018 and the number of shares beneficially owned following the transaction.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.18 to $30.62 per share, inclusive.
The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.
From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
/s/ John Heard, as attorney-in-fact
2019-01-18